Company: TELO
Filing Date: 2025-08-07
Form Type: 8-K
Source: 0001641172-25-022506
Chunk: 1

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-08-07
Form: 8-K
Item: Item 8.01
Chunk 1
---
1 in PC3 xenograft prostate cancer models. In head-to-head comparisons, Telomir-1 demonstrated
more complete reactivation of STAT1 than either Paclitaxel or Rapamycin.

These
results provide important insight into Telomir-1’s mechanism of action and support its continued development across oncology and
other age-related therapeutic areas. The company is currently preparing to advance Telomir-1 into IND-enabling studies.

SIGNATURES

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

                             TELOMIR PHARMACEUTICALS, INC.                               
  Dated: August 7, 2025      By:                                /s/                      
                             Name:                              Erez Aminov              
                             Title:                             Chief Executive Officer